Efficacy and Viral Dynamics of Tecovirimat in Patients with MPOX: A Multicenter Open-Label, Double-Arm Trial in Japan
Preprint
Abstract
Introduction: Tecovirimat’s application in treating mpox remains under-researched, leaving gaps in clinical and virological understanding. Methods: The Tecopox study, conducted in Japan, assessed the efficacy and safety of oral tecovirimat therapy in patients with smallpox or mpox. Patients with mpox enrolled between June 28, 2022, and April 30, 2023, were included. We gathered demographic and clinical details along with blood, urine, pharyngeal swab, and skin lesion samples for viral analysis. A multivariable Tobit regression model was employed to identify factors influencing prolonged viral detection. Results: Nineteen patients were allocated to the tecovirimat group. The median age was 38.5 years, and all were male. Ten patients (52.6%) were infected with the human immunodeficiency virus (HIV). Sixteen patients (84.2%) had severe disease. Nine of the 15 patients (60.0%) (four patients withdrew before day 14) had negative PCR results for skin lesion specimens 14 days after inclusion. The mortality rates on days 14 and 30 were 0% and 0%, respectively. No severe adverse events were reported. HIV status and the number of days from symptom onset to tecovirimat administration were associated with lower Ct values ( p = 0.027 and p < 0.001, respectively). The median number of days when PCR testing did not detect the mpox virus in each patient was 19.5 days. Conclusion: The results suggest that early tecovirimat administration might reduce viral shedding duration, thereby mitigating infection spread. Moreover, patients infected with HIV appeared to have prolonged viral shedding, increasing the transmission risk compared to those without HIV. Keypoints: The Tecopox study revealed that early tecovirimat administration might reduce viral shedding duration, thereby mitigating infection spread. Moreover, patients infected with HIV appeared to have prolonged viral shedding, increasing the transmission risk compared to those without HIV.Keywords
All Related Versions
- Published version: Journal of Infection and Chemotherapy, 30 (6), 488.
This publication has 10 references indexed in Scilit:
- Clinical Presentation of Mpox in People With and Without HIV in the United Kingdom During the 2022 Global OutbreakAIDS Research and Human Retroviruses, 2023
- Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypoxBMJ Open, 2023
- Tecovirimat for the treatment of severe Mpox in GermanyInfection, 2023
- Tecovirimat Treatment of People With HIV During the 2022 Mpox OutbreakAnnals of Internal Medicine, 2023
- Notes from the Field: Posttreatment Lesions After Tecovirimat Treatment for Mpox — New York City, August–September 2022MMWR. Morbidity and Mortality Weekly Report, 2023
- Tecovirimat concentrations and viral suppression in seminal fluid from patients with mpoxThe Lancet Infectious Diseases, 2023
- Monkeypox virus isolation from longitudinal samples from four patients to infer risk of onwards transmission: an interim analysisJournal of Hospital Infection, 2023
- Therapeutics for treating mpox in humansCochrane Database of Systematic Reviews, 2023
- Viral dynamics in patients with monkeypox infection: a prospective cohort study in SpainThe Lancet Infectious Diseases, 2022
- Tecovirimat therapy for severe monkeypox infection: Longitudinal assessment of viral titers and clinical response pattern—A first case‐series experienceJournal of Medical Virology, 2022